ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

ClinicalTrials.gov ID: NCT00376935

Public ClinicalTrials.gov record NCT00376935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less

Study identification

NCT ID
NCT00376935
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
99 participants

Conditions and interventions

Conditions

Interventions

  • Palifermin Drug
  • Palifermin placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
Jun 30, 2008
Completion
Aug 31, 2008
Last update posted
Nov 3, 2021

2006 – 2008

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
18
Facility City State ZIP Site status
USC CRS Los Angeles California 90033
UCLA CARE Center CRS Los Angeles California 90035
Stanford CRS Palo Alto California 94304
Ucsd, Avrc Crs San Diego California 92103
Harbor-UCLA Med. Ctr. CRS Torrance California 90502
Univ. of Miami AIDS CRS Miami Florida 33136-1013
The Ponce de Leon Ctr. CRS Atlanta Georgia 30308
IHV Baltimore Treatment CRS Baltimore Maryland 21201
Bmc Actg Crs Boston Massachusetts 02118
Washington U CRS St Louis Missouri 63108-2138
NY Univ. HIV/AIDS CRS New York New York 10016
Columbia P&S CRS New York New York 10032-3732
Trillium Health ACTG CRS Rochester New York 14607
Univ. of Rochester ACTG CRS Rochester New York 14642
Unc Aids Crs Chapel Hill North Carolina 27514
Duke Univ. Med. Ctr. Adult CRS Durham North Carolina 27710
Case CRS Cleveland Ohio 44106
MetroHealth CRS Cleveland Ohio 44109
The Ohio State University Medical Center Columbus Ohio 43210
Hosp. of the Univ. of Pennsylvania CRS Philadelphia Pennsylvania 19104
Vanderbilt Therapeutics CRS Nashville Tennessee 37204
University of Washington AIDS CRS Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00376935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2021 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00376935 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →